Target intelligence / Profile preview

D-alanyl-D-alanine terminus of peptidoglycan precursor (D-Ala-D-Ala) (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall component, Peptidoglycan precursor, Other
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus is a critical structural motif found at the end of the pentapeptide chains of peptidoglycan precursors in Gram-positive bacteria (Nature Reviews Microbiology, 2008). It serves as the essential substrate for penicillin-binding proteins (PBPs), which catalyze the transpeptidation and transglycosylation reactions necessary for bacterial cell wall cross-linking and stability (StatPearls, 2023). This motif is the primary therapeutic target for glycopeptide antibiotics, such as vancomycin and teicoplanin (PubChem, 2024). These drugs bind to the D-Ala-D-Ala terminus through a network of five hydrogen bonds, creating a molecular cap that sterically hinders the enzymatic assembly of the cell wall (Journal of Biological Chemistry, 1994). Disruption of this process leads to cell wall weakening and eventual osmotic lysis of the bacterium. Resistance to these drugs often involves the metabolic reprogramming of the cell wall synthesis pathway to replace the terminal D-alanine with D-lactate or D-serine, which significantly reduces drug binding affinity by removing a key hydrogen bond (Nature Reviews Microbiology, 2008).

Other names
D-alanyl-D-alanine dipeptidePeptidoglycan pentapeptide terminusUDP-N-acetylmuramyl-pentapeptide terminusD-Ala-D-Ala motif
02

Mechanism of action

Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus via a network of hydrogen bonds, which sterically hinders the transglycosylation and transpeptidation enzymes (penicillin-binding proteins) from incorporating the precursor into the peptidoglycan layer (StatPearls, 2023; Nature Reviews Microbiology, 2008).

03

Biological functions

Bacterial cell wall biosynthesisPeptidoglycan cross-linkingOther
04

Disease associations

Infection
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndrome (infusion-related reaction)Development of Vancomycin-resistant Enterococci (VRE)Development of Vancomycin-resistant Staphylococcus aureus (VRSA)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

VanA gene clusterVanB gene clusterD-alanyl-D-lactate (D-Ala-D-Lac) substitutionD-alanyl-D-serine (D-Ala-D-Ser) substitution

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of peptidoglycan precursor (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan precursor (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call